Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

PRAX

Praxis Precision Medicines Inc

Feb 09 • 04:00PM ET

319.54

-0.03 -0.01 %

Healthcare • Biotechnology • USA • NASD

Peers: SAGE ITCI ACAD NBIX BHVN AXSM VNDA RLMD HELP DFTX

| Held by: VTI IWM XBI VXF IWN IBB SCHA VTWO IWC VHT

Index	RUT	P/E	-	EPS (ttm)	-12.90	Insider Own	7.76%	Shs Outstand	27.41M	Perf Week	3.37%
Market Cap	8.76B	Forward P/E	-	EPS next Y	-12.63	Insider Trans	-1.79%	Shs Float	25.28M	Perf Month	8.55%
Enterprise Value	8.49B	PEG	-	EPS next Q	-3.10	Inst Own	83.77%	Short Float	14.83%	Perf Quarter	85.40%
Income	-273.04M	P/S	1173.95	EPS this Y	-28.09%	Inst Trans	-4.66%	Short Ratio	4.90	Perf Half Y	595.56%
Sales	7.46M	P/B	19.69	EPS next Y	3.43%	ROA	-67.20%	Short Interest	3.75M	Perf YTD	8.41%
Book/sh	16.23	P/C	32.78	EPS next 5Y	16.28%	ROE	-75.20%	52W High	326.91 -2.25%	Perf Year	265.56%
Cash/sh	9.75	P/FCF	-	EPS past 3/5Y	44.28% 8.54%	ROIC	-79.49%	52W Low	26.70 1096.78%	Perf 3Y	344.73%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	97.87%	Volatility	5.87% 6.17%	Perf 5Y	-59.30%
Dividend TTM	-	EV/Sales	1138.20	EPS Y/Y TTM	-25.33%	Oper. Margin	-3927.51%	ATR (14)	18.19	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	5.18	Sales Y/Y TTM	364.98%	Profit Margin	-3658.53%	RSI (14)	60.38	Recom	1.44
Dividend Gr. 3/5Y	- -	Current Ratio	5.18	EPS Q/Q	-22.38%	SMA20	4.13%	Beta	2.90	Target Price	570.38
Payout	-	Debt/Eq	0.00	Sales Q/Q	-100.00%	SMA50	14.91%	Rel Volume	0.49	Prev Close	319.57
Employees	116	LT Debt/Eq	0.00	Earnings	Nov 05 BMO	SMA200	158.60%	Avg Volume	765.49K	Price	319.54
IPO	Oct 16, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	3.06% -100.00%	Trades		Volume	376,289	Change	-0.01%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-02-26	Initiated	Wells Fargo	Equal Weight	$282
Dec-15-25	Reiterated	Oppenheimer	Outperform	$250 → $750
Nov-19-25	Initiated	BTIG Research	Buy	$424
Jun-02-25	Resumed	Oppenheimer	Outperform	$97
May-07-25	Initiated	Chardan Capital Markets	Buy	$80
Mar-03-25	Reiterated	H.C. Wainwright	Buy	$120 → $105
Feb-11-25	Initiated	Deutsche Bank	Buy	$111
Aug-05-24	Initiated	Oppenheimer	Outperform	$134
Jun-24-24	Initiated	Needham	Buy	$145
Jun-18-24	Initiated	Guggenheim	Buy	$155
May-01-24	Initiated	Robert W. Baird	Outperform	$117
Sep-19-23	Initiated	Truist	Buy	$10
Jun-06-22	Downgrade	Wedbush	Outperform → Neutral	$4
Dec-16-21	Initiated	H.C. Wainwright	Buy	$48
Aug-26-21	Initiated	BofA Securities	Buy	$28
Apr-26-21	Initiated	William Blair	Outperform
Nov-11-20	Initiated	Wedbush	Outperform	$40
Nov-10-20	Initiated	Piper Sandler	Overweight	$65
Nov-10-20	Initiated	Evercore ISI	Outperform	$55
Nov-10-20	Initiated	Cowen	Outperform

Show Previous Ratings

Feb-09-26 04:01PM	Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-04-26 04:01PM	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-03-26 06:40AM	SEQSTER and Praxis expand collaboration to expedite CNS disorder trials (Clinical Trials Arena)
Feb-02-26 09:47AM	Palantir upgraded, Best Buy downgraded: Wall Street's top analyst calls (The Fly)
Jan-15-26 11:35AM	Praxis Precision Medicines, Inc. (PRAX) a Strong Buy, Per Wall Street Consensus (Insider Monkey)
04:30PM	Loading…
Jan-13-26 04:30PM	Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy (GlobeNewswire) +6.28%
Jan-12-26 08:00AM	Praxis Precision Medicines Enters Its Next Chapter Following a Pivotal Year of Progress (GlobeNewswire)
Jan-11-26 01:07AM	Needham Analyst Keeps a Buy Rating on Praxis Precision Medicines, Inc. (PRAX) (Insider Monkey)
Jan-09-26 04:01PM	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-08-26 04:45PM	Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments (GlobeNewswire)
Jan-06-26 11:15PM	Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering (GlobeNewswire) +7.23%
04:03PM	Praxis Precision Medicines, Inc. Announces Proposed Public Offering (GlobeNewswire)
Dec-30-25 08:05AM	Praxis Precision granted Breakthrough Therapy designation for Ulixacaltamide (TipRanks)
Dec-29-25 07:39PM	Why Praxis Precision Medicines Stock Popped Today (Motley Fool) +13.25%
04:32PM	Stocks Settle Lower as Weakness in Big Tech Weighs (Barchart)
10:02AM	Loading…
10:02AM	Stocks Slip Due to Weakness in Megacap Technology Stocks (Barchart)
08:00AM	Praxis Precision Medicines Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor (GlobeNewswire)
07:52AM	Here Are Mondays Top Wall Street Analyst Research Calls: Doximity, KB Home, NVIDIA, Okta, On Holdings, Take-Two Interactive, Vail Resorts, and More (24/7 Wall St.)
Dec-12-25 05:18AM	Praxis tees up another approval filing; Geron turns to layoffs (BioPharma Dive)
Dec-11-25 08:00AM	Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026 (GlobeNewswire)
07:44AM	TD Cowen Lifts Praxis Precision Medicines Inc. (PRAX) Price Target amid NDA for Essential Tremor Treatment (Insider Monkey)
Dec-09-25 04:01PM	Praxis Precision Medicines Announces Alignment with FDA on Simplified and Accelerated Registrational Pathway for Elsunersen in Early Onset SCN2A Developmental and Epileptic Encephalopathy (GlobeNewswire)
12:20AM	Praxis Precision Medicines Inc. (PRAX) Secures Analyst Confidence After Key FDA and Trial Wins (Insider Monkey)
Dec-08-25 10:39AM	PRAX Stock Skyrockets 520% in 3 Months: Here's What You Need to Know (Zacks) +9.27%
08:00AM	Praxis AES Wrap-up: Best-in-Class Potential Across Rare Pediatric and Adult Epilepsies (GlobeNewswire)
Dec-05-25 04:58PM	Health Care Roundup: Market Talk (The Wall Street Journal) +30.54%
04:15PM	Praxis Surges 31%, Hitting Another 3-Year High, On A Surprise Win In Epilepsy (Investor's Business Daily)
12:34PM	Stock Market Today: S&P 500 and Nasdaq Gain For Fourth Straight Day Ahead of Highly-Anticipated Fed Policy Meeting (TheStreet)
12:34PM	Stock Market Today: Nasdaq, Dow Gain As Consumer Sentiment Rises for First Time in Five Months (TheStreet)
05:00AM	Praxis soars higher; Bristol Myers CAR-T therapy wins broader use (BioPharma Dive)
04:10PM	Loading…
Dec-04-25 04:10PM	Praxis Precision Medicines Announces Positive Results from EMBOLD Study for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies (GlobeNewswire)
04:01PM	Praxis Precision Medicines Announces Positive Pre-NDA Meeting with FDA for Ulixacaltamide in Essential Tremor (GlobeNewswire)
Dec-03-25 04:01PM	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-24-25 04:01PM	Praxis to present latest preclinical and clinical advancements across leading epilepsy portfolio at the 2025 American Epilepsy Society (AES) Annual Meeting (GlobeNewswire) +12.40%
Nov-20-25 04:01PM	Praxis Precision Medicines to Participate in Upcoming Fireside Chat (GlobeNewswire) -13.33%
Nov-19-25 09:07AM	Here Are Wednesdays Top Wall Street Analyst Research Calls: DoorDash, Freeport-McMoRan, GitLab, Home Depot, Medtronic, Molson-Coors, and More (24/7 Wall St.)
Nov-06-25 08:00AM	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-05-25 04:01PM	Praxis Precision Medicines to Participate in Upcoming Investor Conferences (GlobeNewswire)
08:00AM	Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Nov-04-25 08:00AM	Praxis announces accelerated development path for relutrigine in SCN2A and SCN8A DEE patients following positive FDA feedback (GlobeNewswire) -5.63%
Nov-03-25 11:15AM	Oppenheimer Lifts Price Target for Praxis Medicines (PRAX), Keeps Outperform Rating (Insider Monkey) -8.44%
Oct-29-25 10:00AM	Praxis Precision Medicines, Inc. (PRAX) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-26-25 03:47AM	Meet the Biotech Stock That Just Jumped 251% Higher (Motley Fool)
Oct-22-25 07:41AM	Praxis Precision Medicines Reports Positive Phase 3 Results for Ulixacaltamide in Essential Tremor (Insider Monkey)
Oct-17-25 10:09AM	Praxis Precision (PRAX) Triples on Stellar Drug Trial Results (Insider Monkey) +16.77%
09:10AM	Praxis Precision Medicines (PRAX) Surges 183.7%: Is This an Indication of Further Gains? (Zacks)
08:49AM	Tesla, Nvidia, Rigetti, Praxis: Trending Stocks (Yahoo Finance Video)
Oct-16-25 11:45PM	Praxis Precision Medicines, Inc. Announces Pricing of $525 Million Public Offering (GlobeNewswire) +183.71%
04:01PM	Praxis Precision Medicines, Inc. Announces Proposed Public Offering (GlobeNewswire)
03:49PM	Praxis Precision surges, analysts see blockbuster potential for ulixacaltamide (Investing.com)
02:14PM	Praxis Precision's tremor-drug trial has succeeded where others have failed. The stock is skyrocketing. (MarketWatch)
12:07PM	A Treatment for Tremors Is Back From the Dead. This Stock Is Up 200%. (Barrons.com)
11:53AM	The 'Groundbreaking' Results That Sent Praxis Precision Medicines Up 200% (Investor's Business Daily)
11:35AM	This Strong Buy Stock Has More Than Tripled Today. Should You Buy It Here? (Barchart)
08:21AM	A longshot bet on a tremor drug pays off (BioPharma Dive)
07:00AM	Praxis Precision Medicines Announces Positive Topline Results from Two Pivotal Phase 3 Studies of Ulixacaltamide HCl in the Essential3 Program for Essential Tremor (GlobeNewswire)
Oct-02-25 04:01PM	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-29-25 07:00AM	ReCode Therapeutics Announces Over $29 Million in Additional Financing to Advance Genetic Medicines Pipeline and Provides Corporate Update (Business Wire)
Sep-04-25 04:01PM	Praxis Precision Medicines to Participate in September Investor Conferences (GlobeNewswire)
Sep-03-25 04:01PM	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-29-25 08:00AM	Praxis Precision Medicines to Participate in Upcoming Fireside Chat (GlobeNewswire)
Aug-25-25 04:01PM	Praxis Medicines to Present at 36th International Epilepsy Congress 2025 in Lisbon, Showcasing Latest RADIANT Study Data and Leading Precision Epilepsy Pipeline (GlobeNewswire)
Aug-06-25 04:01PM	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-05-25 06:09PM	Praxis Precision Medicines to Participate in Upcoming Fireside Chat (GlobeNewswire) -6.46%
07:38AM	Praxis vormatrigine eliminates seizures in 22% of patients in Phase II trial (Clinical Trials Arena)
03:01AM	Praxis Precision Medicines Inc (PRAX) Q2 2025 Earnings Call Highlights: Vormatrigine Shows ... (GuruFocus.com)
Aug-04-25 08:24PM	Praxis Precision Medicines to Participate in Upcoming Fireside Chat (GlobeNewswire) -5.55%
01:38PM	Praxis' Epilepsy Treatment Shows Promise With Decreased Seizures (Benzinga)
08:30AM	Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2025 Financial Results (GlobeNewswire)
08:23AM	A brain biotech slumps even with best case seizure data (BioPharma Dive)
08:00AM	Praxis Precision Medicines Announces Positive, Best-in-Disease Topline Results in Patients with Focal Onset Seizures from the RADIANT Study of Vormatrigine (GlobeNewswire)
Jul-29-25 08:00AM	Praxis Precision Medicines to Host Conference Call to Announce Topline Results from the RADIANT Trial and Provide Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-17-25 08:00AM	Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Relutrigine for the Treatment of Seizures Associated with SCN2A and SCN8A Developmental and Epileptic Encephalopathies (GlobeNewswire)
Jul-10-25 08:00AM	Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity (Investor's Business Daily)
Jul-02-25 05:00PM	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.30%
Jun-24-25 05:42PM	Truist Financial Remains Bullish on Praxis Precision Medicines (PRAX) (Insider Monkey) +5.60%
Jun-04-25 05:00PM	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-20-25 08:00AM	Praxis Precision Medicines to Participate in Upcoming Conferences (GlobeNewswire) +6.29%
May-05-25 08:00AM	Praxis Precision Medicines Highlights DEE Clinical Program Updates at Virtual Investor Event (GlobeNewswire)
May-02-25 05:00PM	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.73%
08:30AM	Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results (GlobeNewswire)
Apr-08-25 08:00AM	Praxis Precision Medicines to Hold Virtual Investor Event to Discuss Clinical Programs in Developmental and Epileptic Encephalopathies (GlobeNewswire) -9.29%
Apr-03-25 05:00PM	Praxis Precision Medicines to Participate in Upcoming April Conferences (GlobeNewswire) -10.27%
04:00PM	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-24-25 08:00AM	Praxis Precision Medicines to Present on Late-Stage Programs across Epilepsy and Movement Disorders at the American Academy of Neurology 2025 Annual Meeting (GlobeNewswire)
Mar-04-25 05:00PM	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.93%
08:05AM	Praxis Precision price target lowered to $85 from $150 at Needham (TipRanks)
08:00AM	Praxis Precision Medicines to Participate in Five Upcoming Investor Conferences (GlobeNewswire)
Feb-28-25 09:10AM	Praxis Precision Medicines, Inc. (PRAX) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -40.64%
08:00AM	Praxis Precision Medicines Provides Update on Essential3 and Corporate Update (GlobeNewswire)
06:40AM	Praxis hits trial setback; Bristol Myers lays off staff in New Jersey (BioPharma Dive)
Feb-25-25 10:00AM	Praxis Precision Medicines, Inc. (PRAX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release (Zacks)
Feb-04-25 05:00PM	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.68%
Feb-03-25 05:00PM	Praxis Precision Medicines to Present at Two February Investor Conferences (GlobeNewswire)
Jan-12-25 09:00PM	Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities (GlobeNewswire)
Jan-06-25 08:00AM	Praxis Precision Medicines to Present at J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-18-24 08:00AM	Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome (GlobeNewswire)
Dec-05-24 08:30AM	GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners (Business Wire) -8.18%
Dec-03-24 08:00AM	Praxis Precision Medicines to Present at Upcoming December Investor Conferences (GlobeNewswire) -7.39%
Nov-26-24 08:00AM	Praxis Precision Medicines to Showcase Updates from Largest Epilepsy Pipeline of Precision Epilepsy Programs at the 2024 American Epilepsy Society Annual Meeting (GlobeNewswire) +6.67%

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. It focuses on two proprietary platforms: Cerebrum and Solidus. The Cerebrum platform utilizes a deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies. The Solidus platform consists of antisense oligonucleotide, or ASO. The company was founded by Kiran Reddy, David Goldstein, and Steven Petrou on September 22, 2015 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Nemiroff Alex	General Counsel and Secretary	Nov 20 '25	Option Exercise	73.76	25,130	1,853,531	45,962	Nov 21 09:41 PM
Nemiroff Alex	General Counsel and Secretary	Nov 20 '25	Sale	193.09	25,130	4,852,256	20,832	Nov 21 09:41 PM
Mastrocola Lauren	Principal Accounting Officer	Nov 20 '25	Option Exercise	61.12	13,600	831,257	24,042	Nov 21 09:39 PM
Mastrocola Lauren	Principal Accounting Officer	Nov 20 '25	Sale	192.08	13,600	2,612,244	10,442	Nov 21 09:39 PM
Nemiroff Alex	Officer	Nov 20 '25	Proposed Sale	193.09	25,130	4,852,249		Nov 20 11:34 AM
Mastrocola Lauren	Officer	Nov 20 '25	Proposed Sale	192.08	13,600	2,612,239		Nov 20 11:25 AM
MITCHELL DEAN J	Director	Sep 24 '25	Option Exercise	39.51	12,251	483,991	17,251	Sep 25 04:40 PM

Open in Screener

SLDB

Solid Biosciences Inc

Feb 09 • 04:00PM ET

6.86

+0.34 5.21 %

Healthcare • Biotechnology • USA • NASD

SLDB Solid Biosciences Inc daily Stock Chart

Peers: SRPT PFE BMRN BLUE QURE EDIT RGEN NTLA ABEO VYGR

| Held by: VTI IWM IWN IBB VXF VTWO DFAS IWC PRFZ AVSC

Index	RUT	P/E	-	EPS (ttm)	-2.49	Insider Own	25.12%	Shs Outstand	77.88M	Perf Week	6.69%
Market Cap	534.46M	Forward P/E	-	EPS next Y	-2.04	Insider Trans	-1.94%	Shs Float	58.34M	Perf Month	29.19%
Enterprise Value	320.26M	PEG	-	EPS next Q	-0.50	Inst Own	83.47%	Short Float	14.74%	Perf Quarter	62.75%
Income	-167.13M	P/S	-	EPS this Y	31.42%	Inst Trans	3.32%	Short Ratio	8.20	Perf Half Y	9.06%
Sales	0.00M	P/B	2.45	EPS next Y	2.94%	ROA	-68.82%	Short Interest	8.60M	Perf YTD	21.63%
Book/sh	2.80	P/C	2.26	EPS next 5Y	14.41%	ROE	-86.83%	52W High	7.37 -6.92%	Perf Year	119.17%
Cash/sh	3.03	P/FCF	-	EPS past 3/5Y	32.97% 41.25%	ROIC	-70.35%	52W Low	2.41 184.65%	Perf 3Y	-8.66%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	8.97% 7.27%	Perf 5Y	-93.44%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	17.88%	Oper. Margin	-	ATR (14)	0.43	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.74	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	63.75	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	6.74	EPS Q/Q	38.60%	SMA20	10.37%	Beta	2.65	Target Price	15.75
Payout	-	Debt/Eq	0.10	Sales Q/Q	-	SMA50	17.21%	Rel Volume	1.87	Prev Close	6.52
Employees	100	LT Debt/Eq	0.09	Earnings	Nov 03 AMC	SMA200	30.77%	Avg Volume	1.05M	Price	6.86
IPO	Jan 26, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	-9.34% -	Trades		Volume	1,962,528	Change	5.21%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-04-25	Initiated	Needham	Buy	$16
Jun-26-25	Initiated	Citigroup	Buy	$14
Jan-08-25	Initiated	Truist	Buy	$16
Dec-13-24	Initiated	Wedbush	Outperform	$16
Dec-10-24	Initiated	JMP Securities	Mkt Outperform	$15
Jul-15-24	Upgrade	JP Morgan	Neutral → Overweight	$10 → $15
Jun-24-24	Upgrade	Leerink Partners	Market Perform → Outperform	$12
May-31-24	Resumed	Piper Sandler	Overweight	$20
Mar-28-24	Initiated	William Blair	Outperform	$40
Mar-15-24	Initiated	Citigroup	Buy	$16
Mar-14-24	Upgrade	Piper Sandler	Neutral → Overweight	$8 → $20
Dec-08-23	Initiated	H.C. Wainwright	Buy	$9
Jul-12-21	Initiated	Piper Sandler	Neutral	$6
May-27-21	Initiated	Jefferies	Buy	$7
Mar-16-21	Upgrade	SVB Leerink	Mkt Perform → Outperform	$3 → $15
Mar-09-21	Initiated	Barclays	Overweight	$13
Jan-08-21	Upgrade	Credit Suisse	Underperform → Neutral	$2 → $7
Jul-28-20	Downgrade	SVB Leerink	Outperform → Mkt Perform
May-07-20	Downgrade	Evercore ISI	Outperform → In-line
Oct-11-19	Initiated	Evercore ISI	Outperform	$22

Show Previous Ratings

Feb-09-26 08:00AM	Solid Biosciences Announces Positive Feedback from Type C Meeting with FDA for SGT-003 Gene Therapy for Duchenne Muscular Dystrophy (GlobeNewswire) +5.21%
Feb-06-26 08:00AM	Solid Biosciences to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 (GlobeNewswire)
Jan-26-26 02:49PM	Sarepta Stock Climbs. 3-Year Study Results for Elevidys Bring Hope. (Barrons.com)
Jan-16-26 09:08AM	Will KROS Stock's Restructuring Efforts Reap Rewards for Investors? (Zacks)
Jan-15-26 12:58PM	JPM26: Solid Biosciences banks on its AAV capsid to catalyse gene therapy success (Pharmaceutical Technology)
04:15PM	Loading…
Jan-13-26 04:15PM	Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101 (GlobeNewswire) +12.60%
Jan-12-26 04:15PM	Solid Biosciences Receives FDA Orphan Drug Designation for SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich's Ataxia (GlobeNewswire)
08:05AM	Solid Biosciences Doses First Participant in First-in-Class Phase 1b FALCON Trial Evaluating SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich's Ataxia (GlobeNewswire)
Jan-06-26 08:00AM	Solid Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-05-26 04:15PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-16-25 04:51PM	Solid Biosciences Announces Duchenne Muscular Dystrophy Added to National Recommended Uniform Screening Panel by the U.S. Department of Health and Human Services (GlobeNewswire) -7.56%
Dec-15-25 11:10PM	Sarepta's Elevidys Safety Concerns Open Major Opportunity for Solid Biosciences' (SLDB) SGT-003 in Duchenne Therapy (Insider Monkey)
Dec-08-25 08:00AM	Solid Biosciences to Showcase Proprietary Next-Generation Capsid AAV-SLB101 and Cardiac Gene Therapy Pipeline at the 22nd Global CardioVascular Clinical Trialists (CVCT) Forum (GlobeNewswire)
Dec-02-25 06:54AM	Solid Biosciences' SGT-212 gains FDA rare paediatric disease status (Pharmaceutical Business Review)
Dec-01-25 04:05PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Loading…
08:00AM	Solid Biosciences Receives FDA Rare Pediatric Disease Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich's Ataxia (GlobeNewswire)
Nov-17-25 08:00AM	Solid Biosciences Announces Licensing Agreement with Andelyn Biosciences for the Use of Proprietary Next-Generation Capsid AAV-SLB101 (GlobeNewswire)
Nov-11-25 08:00AM	Solid Biosciences to Participate at Upcoming Investor Conferences (GlobeNewswire) +9.16%
Nov-06-25 08:00AM	Solid Biosciences Awarded Innovation Passport Designation Under the New UK Innovative Licensing and Access Pathway for SGT-003, an Investigational Gene Therapy for Duchenne Muscular Dystrophy (GlobeNewswire) +7.25%
Nov-04-25 04:05PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -15.29% -10.78%
Nov-03-25 04:05PM	Solid Biosciences Reports Third Quarter 2025 Financial Results and Provides Update on INSPIRE DUCHENNE Clinical Trial Progress and Planned Regulatory Discussions (GlobeNewswire)
Oct-30-25 08:00AM	Solid Biosciences to Participate at Upcoming Investor Conferences (GlobeNewswire)
Oct-01-25 04:05PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Solid Biosciences to Present at Upcoming Scientific Meetings (GlobeNewswire)
Sep-25-25 08:00AM	Solid Biosciences to Present at 2025 Neuromuscular Study Group Annual Scientific Meeting (GlobeNewswire) -5.13%
Sep-23-25 08:00AM	Solid Biosciences Announces Licensing Agreement with Kinea Bio for the Use of Proprietary Next-Generation Capsid AAV-SLB101 (GlobeNewswire)
Sep-18-25 09:10AM	Anti-Aging Biotech Surges as $101M Competition Ignites Global Race Against Aging Demographics (PR Newswire)
Aug-28-25 08:00AM	Solid Biosciences to Participate at Upcoming Investor Conferences (GlobeNewswire)
Aug-12-25 04:07PM	Solid Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire) +10.60%
03:33PM	Brutal 2025 for Sarepta-Analysts Still Call for 179% Upside (MarketBeat)
08:00AM	Loading…
Aug-01-25 08:00AM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-23-25 08:00AM	Solid Biosciences Receives FDA Fast Track Designation for SGT-501 First-in-Class Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) (GlobeNewswire) +8.51%
Jul-21-25 08:30AM	Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors (GlobeNewswire)
Jul-09-25 10:17AM	Citi Initiates Coverage on Solid Biosciences Inc. (SLDB) with 'Buy' Rating and $14 PT (Insider Monkey) +5.34%
Jul-08-25 04:05PM	Solid Biosciences Announces FDA IND and Health Canada CTA Approval for First-in-Class Cardiac Gene Therapy to Treat Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) (GlobeNewswire) +6.72%
Jul-01-25 04:05PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.54% +5.87%
Jun-26-25 09:49AM	General Mills upgraded, Trade Desk downgraded: Wall Street's top analyst calls (The Fly)
Jun-18-25 11:39AM	Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences (MarketBeat)
Jun-03-25 08:00AM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-28-25 08:00AM	Solid Biosciences to Participate at the Jefferies Global Healthcare Conference (GlobeNewswire) +7.24%
May-15-25 04:06PM	Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire) +6.95%
May-01-25 04:00PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +10.27% +18.08%
Apr-30-25 08:00AM	Solid Biosciences to Participate at The Citizens Life Sciences Conference (GlobeNewswire) +8.52%
Apr-29-25 08:00AM	Solid Biosciences to Present at the American Society of Gene and Cell Therapy's 28th Annual Meeting (GlobeNewswire) -5.57%
Apr-08-25 04:50PM	Solid Biosciences: A Strong Buy As An Emerging Biotech In The Gene Therapy Space (Seeking Alpha) -9.18%
07:30AM	Can Solid Biosciences Challenge Sarepta in the DMD Market? (MarketBeat)
Apr-07-25 08:00AM	Solid Biosciences to Participate at Upcoming Investor Conferences (GlobeNewswire) -5.62%
Apr-01-25 08:00AM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.89%
07:00AM	Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors (GlobeNewswire)
Mar-26-25 12:31PM	5 Reasons To Buy Regenxbio Right Now (SeekingAlpha) -5.12%
Mar-14-25 10:29PM	Solid Biosciences Inc. (SLDB): Among Top Insider Purchases Last Month (Insider Monkey) +5.30%
Mar-12-25 08:00AM	Solid Biosciences to Present at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference (GlobeNewswire)
Mar-07-25 09:55AM	Wall Street Analysts Believe Solid Biosciences (SLDB) Could Rally 198.18%: Here's is How to Trade (Zacks)
Mar-06-25 04:16PM	Solid Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-05-25 08:00AM	Solid Biosciences to Participate at Upcoming Investor Conferences (GlobeNewswire) +8.47%
Mar-04-25 08:33PM	Is Solid Biosciences Inc. (SLDB) Among Stocks With At Least $20 Million In Insider Spending Recently? (Insider Monkey)
04:07PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-19-25 08:02AM	Solid Biosciences stock soars on early success in DMD gene therapy trial (Clinical Trials Arena) +22.08%
Feb-18-25 07:00AM	Solid Biosciences Announces Pricing of Underwritten Offering (GlobeNewswire) +31.51%
06:45AM	Solid Biosciences Reports Positive Initial Clinical Data from Next-Generation Duchenne Gene Therapy Candidate SGT-003 (GlobeNewswire)
06:36AM	Solid says early data suggest differentiated Duchenne gene therapy (BioPharma Dive)
Feb-09-25 06:12AM	Analysts Predict Up to ~450% Surge for These 2 Strong Buy Penny Stocks (TipRanks)
Feb-04-25 08:00AM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-21-25 08:30AM	Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich's Ataxia (GlobeNewswire)
Jan-15-25 04:05PM	Solid Biosciences Outlines Key Priorities for Advancing Diversified Neuromuscular and Cardiac Development Pipeline and Establishing Leadership in Precision Genetic Medicines (GlobeNewswire)
Jan-08-25 04:05PM	Solid Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -8.68%
Jan-07-25 04:15PM	Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich's Ataxia (GlobeNewswire)
Jan-06-25 08:00AM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-23-24 04:05PM	Solid Biosciences Added to the Nasdaq Biotechnology Index (GlobeNewswire)
Dec-13-24 01:52PM	Solid Biosciences Positioned For Next-Gen Duchenne Muscular Dystrophy Treatment Success: Analyst (Benzinga)
Dec-04-24 08:05AM	Solid Biosciences reports inducement grant under Nasdaq listing rule (TipRanks)
08:00AM	Solid Biosciences Announces Collaboration with Mayo Clinic to Accelerate Gene Therapy Innovation and Advance Development of Cardiac Gene Therapies (GlobeNewswire)
Dec-03-24 08:00AM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -10.54%
Nov-26-24 08:00AM	Solid Biosciences to Participate at Upcoming Investor Conferences (GlobeNewswire)
Nov-14-24 08:00AM	Solid Biosciences to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
Nov-06-24 04:05PM	Solid Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) -6.03%
Nov-04-24 08:00AM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-31-24 08:00AM	Solid Biosciences to Participate at the Truist Securities BioPharma Symposium (GlobeNewswire)
Oct-02-24 04:15PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-23-24 08:00AM	Solid Biosciences to Participate at Chardan's 8th Annual Genetic Medicines Conference (GlobeNewswire)
Sep-12-24 08:00AM	Solid Biosciences to Participate at the 2024 Cantor Global Healthcare Conference (GlobeNewswire)
Sep-04-24 04:05PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Solid Biosciences to Participate at Upcoming Investor Conferences (GlobeNewswire)
Aug-13-24 04:08PM	Solid Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) +14.54%
Aug-05-24 08:00AM	Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-01-24 04:19PM	Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +10.58%
08:00AM	Solid Biosciences Joins the Russell 3000 Index (GlobeNewswire)
Jun-21-24 07:52AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
Jun-04-24 04:00PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-20-24 06:00AM	3 Must-Buy Biotech Stocks Before the Summer Rally Kicks Off (InvestorPlace)
May-15-24 12:53PM	SLDB Stock Earnings: Solid Biosciences Meets EPS for Q1 2024 (InvestorPlace)
07:52AM	Solid Biosciences Provides First Quarter 2024 Business Update and Financial Results (GlobeNewswire)
May-07-24 07:00AM	Solid Biosciences to Present at the American Society of Gene and Cell Therapy Annual Meeting (GlobeNewswire)
May-02-24 04:05PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.23%
Apr-03-24 04:05PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-02-24 10:35AM	Solid Biosciences (SLDB) Falls Despite FDA Rare Tag for DMD Drug (Zacks)
07:20AM	Solid Biosciences' SGT-003 receives rare pediatric disease designation (Pharmaceutical Business Review)
Apr-01-24 07:45AM	Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003 (GlobeNewswire) -6.61%
Mar-28-24 04:08PM	How Sleeper Biotech Solid Biosciences, With A 687% Gain, Is Making A Comeback (Investor's Business Daily) -6.53%
Mar-27-24 07:00AM	Solid Biosciences to Participate at Cantor's Virtual Muscular Dystrophy Symposium (GlobeNewswire) +5.01%

Solid Biosciences, Inc. is a life science company, which engages in the development of treatments for patients with Duchenne muscular dystrophy. It also focuses on developing treatments for neuromuscular and cardiac diseases. The company was founded by Ilan Ganot, Andrey J. Zarur, Matthew Bennett Arnold, Annie Ganot, and Gilad David Hayeem in March 2013 and is headquartered in Charlestown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Howton David T	Chief Operating Officer	Feb 04 '26	Sale	6.44	18,894	121,713	97,859	Feb 06 06:05 PM
Cumbo Alexander	President and CEO	Feb 04 '26	Sale	6.44	48,913	315,093	222,018	Feb 06 06:01 PM
Ganot Ilan	Director	Feb 04 '26	Sale	6.44	7,205	46,414	25,271	Feb 06 06:01 PM
Tan Kevin	CFO & Treasurer	Feb 04 '26	Sale	6.44	14,783	95,231	94,201	Feb 06 06:00 PM
Brooks Gabriel	Chief Medical Officer	Feb 04 '26	Sale	6.44	12,616	81,271	84,092	Feb 06 05:59 PM
Hanrahan Jessie	Chief Regulatory Officer	Feb 04 '26	Sale	6.44	12,348	79,545	70,327	Feb 06 05:57 PM
Herzich Paul	Chief Technology Officer	Feb 04 '26	Sale	6.44	10,905	70,249	69,067	Feb 06 05:56 PM
Tan Kevin	Officer	Feb 04 '26	Proposed Sale	6.44	14,783	95,227		Feb 04 07:48 PM
Herzich Paul	Officer	Feb 04 '26	Proposed Sale	6.44	10,905	70,247		Feb 04 07:46 PM
Ganot Ilan	Director	Feb 04 '26	Proposed Sale	6.44	7,205	46,412		Feb 04 07:45 PM
Cumbo Alexander	Officer	Feb 04 '26	Proposed Sale	6.44	48,913	315,080		Feb 04 07:44 PM
Howton David T	Officer	Feb 04 '26	Proposed Sale	6.44	18,894	121,708		Feb 04 07:42 PM
Hanrahan Jessie	Officer	Feb 04 '26	Proposed Sale	6.44	12,348	79,541		Feb 04 07:40 PM
Brooks Gabriel	Officer	Feb 04 '26	Proposed Sale	6.44	12,616	81,268		Feb 04 07:37 PM
Tan Kevin	CFO & Treasurer	Feb 02 '26	Sale	6.44	26,837	172,747	108,984	Feb 02 08:18 PM
Cumbo Alexander	President and CEO	Feb 02 '26	Sale	6.44	80,258	516,613	270,931	Feb 02 08:16 PM
Hanrahan Jessie	Chief Regulatory Officer	Feb 02 '26	Sale	6.44	26,535	170,803	82,675	Feb 02 08:15 PM
Brooks Gabriel	Chief Medical Officer	Feb 02 '26	Sale	6.44	28,335	182,390	96,708	Feb 02 08:14 PM
Howton David T	Chief Operating Officer	Feb 02 '26	Sale	6.44	37,771	243,128	116,753	Feb 02 08:12 PM
Herzich Paul	Chief Technology Officer	Feb 02 '26	Sale	6.44	26,250	168,969	79,972	Feb 02 08:09 PM
Hanrahan Jessie	Officer	Feb 02 '26	Proposed Sale	6.44	26,535	170,803		Feb 02 08:07 PM
Brooks Gabriel	Officer	Feb 02 '26	Proposed Sale	6.44	28,335	182,390		Feb 02 08:05 PM
Tan Kevin	Officer	Feb 02 '26	Proposed Sale	6.44	26,837	172,747		Feb 02 08:04 PM
Cumbo Alexander	Officer	Feb 02 '26	Proposed Sale	6.44	80,258	516,613		Feb 02 08:03 PM
Howton David T	Officer	Feb 02 '26	Proposed Sale	6.44	37,771	243,128		Feb 02 08:01 PM
Herzich Paul	Officer	Feb 02 '26	Proposed Sale	6.44	26,250	168,969		Feb 02 07:59 PM
Ganot Ilan	Director	Jan 28 '26	Sale	6.59	191	1,259	17,476	Jan 30 04:05 PM
Tan Kevin	CFO & Treasurer	Jan 13 '26	Sale	5.27	5,704	30,060	46,100	Jan 13 05:02 PM
Tan Kevin	Officer	Jan 13 '26	Proposed Sale	5.27	5,704	30,060		Jan 13 05:00 PM
Ganot Ilan	Director	Jan 05 '26	Sale	5.43	1,053	5,718	17,278	Jan 06 06:52 PM
Howton David T	Chief Operating Officer	Dec 03 '25	Sale	5.11	4,932	25,203	32,908	Dec 04 04:22 PM
Cumbo Alexander	President and CEO	Dec 03 '25	Sale	5.11	10,808	55,229	81,388	Dec 04 04:20 PM
Hanrahan Jessie	Chief Regulatory Officer	Dec 03 '25	Sale	5.11	4,483	22,908	26,660	Dec 04 04:19 PM
Herzich Paul	Chief Technology Officer	Dec 03 '25	Sale	5.11	2,701	13,802	26,622	Dec 04 04:17 PM
Cumbo Alexander	Officer	Dec 03 '25	Proposed Sale	5.11	10,808	55,229		Dec 03 05:07 PM
Ganot Ilan	Director	Nov 10 '25	Sale	4.12	3,278	13,505	95,412	Nov 13 04:05 PM
Brooks Gabriel	Chief Medical Officer	Oct 20 '25	Sale	5.96	2,895	17,254	33,819	Oct 21 04:05 PM
Kahn Clare	Director	Mar 11 '25	Buy	5.34	1,860	9,924	2,960	Mar 13 04:05 PM
Bain Capital Life Sciences Inv	10% Owner	Feb 19 '25	Buy	4.03	1,000,000	4,030,000	5,034,582	Feb 21 05:48 PM
PERCEPTIVE ADVISORS LLC	Director	Feb 19 '25	Buy	4.03	5,000,000	20,150,000	11,833,539	Feb 21 04:17 PM
Adage Capital Management, L.P.	10% Owner	Feb 18 '25	Buy	7.56	252,545	1,909,240	4,248,084	Feb 19 04:16 PM
Hanrahan Jessie	Chief Regulatory Officer	Feb 14 '25	Sale	3.96	3,079	12,193	19,281	Feb 18 04:05 PM
Brooks Gabriel	Chief Medical Officer	Feb 14 '25	Sale	3.96	3,256	12,894	22,812	Feb 18 04:05 PM
Tan Kevin	CFO & Treasurer	Feb 14 '25	Sale	3.96	3,164	12,529	32,250	Feb 18 04:05 PM
Howton David T	Chief Operating Officer	Feb 14 '25	Sale	3.96	5,561	22,022	24,789	Feb 18 04:05 PM
Herzich Paul	Chief Technology Officer	Feb 14 '25	Sale	3.96	2,688	10,644	18,388	Feb 18 04:05 PM
Cumbo Alexander	President and CEO	Feb 14 '25	Sale	3.96	11,365	45,005	60,717	Feb 18 04:05 PM
Ganot Ilan	Director	Feb 14 '25	Sale	3.96	1,711	6,776	14,839	Feb 18 04:05 PM
Howton David T	Officer	Feb 14 '25	Proposed Sale	3.96	5,561	22,022		Feb 14 05:25 PM
Herzich Paul	Officer	Feb 14 '25	Proposed Sale	3.96	2,688	10,644		Feb 14 05:25 PM
Tan Kevin	Officer	Feb 14 '25	Proposed Sale	3.96	3,164	12,529		Feb 14 05:23 PM
Cumbo Alexander	Officer	Feb 14 '25	Proposed Sale	3.96	11,365	45,005		Feb 14 05:23 PM
Hanrahan Jessie	Officer	Feb 14 '25	Proposed Sale	3.96	3,079	12,193		Feb 14 05:20 PM

PRAX

Praxis Precision Medicines Inc

SLDB

Solid Biosciences Inc

Upgrade your FINVIZ experience